Biomarin Pharmaceutical Inc Investor Update Transcript
Welcome to the BioMarin Conference Call to discuss European Approval of ROCTAVIAN. Hosting the conference call today from BioMarin is Traci McCarty, Head of Investor Relations. Please go ahead. Traci.
Thank you very much operator, and thank you all for joining U.S. today to talk about ROCTAVIAN approval in Europe. On the call from BioMarin's management team are J.J. Bienaime, Chairman and Chief Executive Officer; Jeff Ajer, Chief Commercial Officer; Hank Fuchs, President of Worldwide R&D; and Brian Mueller, our Chief Financial Officer.
To remind you, this non-confidential presentation contains forward-looking statements about ROCTAVIAN and the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance and the clinical development and potential regulatory approval of ROCTAVIAN and other commercial products and products and development. Results may differ materially depending on the timing and nature of decisions by regulatory authorities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
